
News
Home>News & Events>Publications>TTC>On September 25th, the FDA published a Personal Viewpoint in the American Journal of Transplantation
357
Related Posts
-
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: the 2019 Expert Consensus From the Transplant Society Working Group
-
Use of Biomarkers to Improve Immunosuppressive Drug Development and Outcomes in Renal Organ Transplantation: A Meeting Report
-
The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients